Inovio Pharmaceuticals Inc
NASDAQ:INO

Watchlist Manager
Inovio Pharmaceuticals Inc Logo
Inovio Pharmaceuticals Inc
NASDAQ:INO
Watchlist
Price: 4.07 USD 0.25% Market Closed
Market Cap: 105.7m USD
Have any thoughts about
Inovio Pharmaceuticals Inc?
Write Note

Inovio Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inovio Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Inovio Pharmaceuticals Inc
NASDAQ:INO
Interest Income Expense
$8.7m
CAGR 3-Years
157%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$598m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Inovio Pharmaceuticals Inc
Glance View

Market Cap
106m USD
Industry
Biotechnology

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.

INO Intrinsic Value
5.99 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Inovio Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
8.7m USD

Based on the financial report for Sep 30, 2024, Inovio Pharmaceuticals Inc's Interest Income Expense amounts to 8.7m USD.

What is Inovio Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
157%

Over the last year, the Interest Income Expense growth was -40%. The average annual Interest Income Expense growth rates for Inovio Pharmaceuticals Inc have been 157% over the past three years .

Back to Top